Bardoxolone
Bardoxolone (RTA 401; CDDO) is an orally active activator of nuclear regulatory factor (NRf-2) and an inhibitor of SARS-CoV-2 3CL protease. Bardoxolone inhibits SARS-CoV-2 3CL protease with an EC50 value of 0.43 μM in vero cells. Bardoxolone also inhibits necroptosis in HT-29 cells with an EC50 value of 1.30 μM by blocking necrosome formation through inhibiting phosphorylation of RIPK1 and RIPK3. Bardoxolone can be used in research on COVID-19, TNF-induced systemic inflammatory response syndrome (SIRS), and cerebral ischemia-reperfusion injury[1][2].
Product Specifications
CAS Number
218600-44-3
Product Name Alternative
CDDO; RTA 401
UNSPSC
12352211
Hazard Statement
H302, H315, H319, H335
Target
Keap1-Nrf2; Necroptosis; SARS-CoV; Virus Protease
Type
Reference compound
Related Pathways
Anti-infection; Apoptosis; NF-κB
Applications
Cancer-Kinase/protease
Field of Research
Infection; Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/Bardoxolone.html
Concentration
10mM
Purity
99.50
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC1(C)CC[C@@]2(C(O)=O)[C@@]([C@](C(C=C3[C@@]4(C)CC[C@]5([H])[C@]3(C)C=C(C#N)C(C5(C)C)=O)=O)([H])[C@@]4(C)CC2)([H])C1
Molecular Formula
C31H41NO4
Molecular Weight
491.66
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
CPNE9 Polyclonal Antibody, PE-Cy5.5 Conjugated
